SAN DIEGO – Cancer screening in the U.S. could soon become a simple part of a routine check-up.
Artificial intelligence-based diagnostics company Craif, Inc., has performed more than 110,000 cancer screenings in Japan since its founding in Tokyo nearly a decade ago. Now, the company plans to use the proceeds of its latest financing round to conduct research and development work at its newly opened San Diego laboratory.
According to CEO Ryuichi Onose, Craif’s business in Japan is growing around 300% each year and is on track to be profitable in 2027.
“Investors really valued our strong growth in Japan, and that’s why we were able to say that what we’re aiming for is success globally, and that’s why we’re going to America,” Onose said.
Ryuichi Onose, CEO of Craif and Takeo Mukai, CFO of Craif. Photos courtesy Craif Unique Genetic Signals in Urine Craif is the developer of a urine-based test for pancreatic cancer, which can detect minute regulatory molecules called microRNA that are carried within particles called extracellular vesicles. American biologists Victor Ambros and Gary Ruvkun received the Nobel Prize in Physiology or Medicine in 2024 for their discovery of microRNA and its ...